Komori
Revision of earnings forecasts2929Pharma Foods International Co.,Ltd.Food

Summary of Financial Results for the Fiscal Year Ended July 2026 (Japanese GAAP) (Consolidated)

The company announced its consolidated results for the fiscal year ended July 2026. Net sales decreased, while operating income and net income attributable to owners of the parent increased; ordinary income decreased. It also newly presented its full-year earnings forecast for the fiscal year ending July 2027.

Worth reading
76Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending July 2027 · Full year
Net Sales—→64,000million
—
Operating profit—→3,000million
—
Ordinary income—→3,400million
—
Profit attributable to owners of the parent—→2,200million
—
Net income per share—→75.75yen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

The company will use its research and development capabilities and business foundation as the foundation for growth, creating and commercialising new value. It will also concentrate management resources in priority areas, with an emphasis on profitability and capital efficiency.

Details and amount of extraordinary loss

Loss on sale of shares in an affiliated company ¥117 million

Previous-period resultsNet sales ¥63,223 million, operating income ¥2,632 million, ordinary income ¥2,440 million, net income attributable to owners of the parent ¥1,988 million, net income per share ¥68.61
Dividend forecast revisionNo revision (full-year dividend forecast of ¥25.00 for the fiscal year ending July 2027)
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net SalesNot disclosed → ¥64,000 million(Change from the previous fiscal year 1.2%)
Operating profitNot disclosed → ¥3,000 million(Change from the previous fiscal year 14.0%)
Ordinary incomeNot disclosed → ¥3,400 million(Change from the previous fiscal year 39.3%)
Profit attributable to owners of the parentNot disclosed → ¥2,200 million(Change from the previous fiscal year 10.7%)
Net income per shareNot disclosed → 75.75 yen
Fiscal Period CoveredFiscal year ending July 2027
Period CoveredFull year
Previous-period resultsNet sales ¥63,223 million, operating income ¥2,632 million, ordinary income ¥2,440 million, net income attributable to owners of the parent ¥1,988 million, net income per share ¥68.61
Reason for the revisionThe company will use its research and development capabilities and business foundation as the foundation for growth, creating and commercialising new value. It will also concentrate management resources in priority areas, with an emphasis on profitability and capital efficiency.
Details and amount of extraordinary lossLoss on sale of shares in an affiliated company ¥117 million
Dividend forecast revisionNo revision (full-year dividend forecast of ¥25.00 for the fiscal year ending July 2027)
Consolidated / non-consolidatedConsolidated
Items this document does not state (1)
Publication date of previous forecast

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explained that it advanced investment in research and development, new product development and the development of sales channels, while reviewing advertising and promotional expenses for existing products and focusing on nurturing new products. For the fiscal year ending July 2027, it plans to create new value by leveraging its research and development capabilities and business foundation, and to concentrate management resources with an emphasis on profitability and capital efficiency.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Fiscal Year Ended July 2026 (Japanese GAAP) (Consolidated) | Pharma Foods International Co.,Ltd. (2929) timely disclosure | Komori